News Story: Full Text
Sponsored By
AbbVie
Please Click On The Above Banner For More Details
Braintumor Website

 

Phase II Trial Shows Favorable Response for Patients Receiving Combination Therapy With SurVaxM

Al's Comment:

 This is very impressive.   93% of GBM patients alive at 1 year compared to 65% historical controls.  This treatment is a simple vaccine injection that does not require brain tumor tissue. It is just a shot in the arm or leg similiar to a flu vaccine, and has minimal to no side effects.  A clinical trial recently opened at the Cleveland Clinic, which will combine a checkpoint inhibitor with the vaccine.


Posted on: 06/03/2019

Phase II Trial Shows Favorable Response for Patients Receiving Combination Therapy With SurVaxM

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740